DIMS 9054

DIMS 9054 is a primary drug candidate for treatment of steroid resistant asthma.

DIMS 9054 is entering preclinical development, and has demonstrated impressive results in animal inflammatory models as well as in human in vitro models.

Intellectual Property
DIMS 9054 has IP protection in Europe for enhancing steroid efficacy in steroid resistant patients.

Mechanism of action Click for picture
DIMS 9054 is a DNA-based immunomodulatory sequence (DIMS) binding to toll-like receptor (TLR) 9 located inside the target cells of the immune system.

DIMS 9054 reduces airway inflammation when glucocorticosteroids are insufficient
 
DIMS 9054 targets several of the features of severe steroid resistant asthma which can not be reversed with steroids alone, making this compound a very attractive drug candidate for a patient group for whom there is very limited medical options.

By restoring steroid sensitivity, DIMS 9054 may reduce the dose or the total need of oral corticosteroids associated with severe side-effects. Besides enhancing the effect of steroids, DIMS 9054 have anti-inflammatory effects by inhibiting migration of inflammatory cells.